tiprankstipranks
Trending News
More News >
MedPeer, Inc. (JP:6095)
:6095
Japanese Market

MedPeer, Inc. (6095) AI Stock Analysis

Compare
0 Followers

Top Page

JP

MedPeer, Inc.

(6095)

Rating:74Outperform
Price Target:
¥782.00
▲(8.61%Upside)
MedPeer, Inc. demonstrates robust financial performance with strong revenue growth and efficient cost management. The low P/E ratio suggests undervaluation, enhancing the stock's appeal. However, the technical analysis indicates potential risks of a pullback due to overbought conditions. Cash flow management requires attention to sustain long-term growth.

MedPeer, Inc. (6095) vs. iShares MSCI Japan ETF (EWJ)

MedPeer, Inc. Business Overview & Revenue Model

Company DescriptionMedPeer, Inc. (6095) operates primarily in the healthcare sector, focusing on providing a platform for doctors to share medical insights and information. The company offers a peer-to-peer online community where physicians can discuss clinical cases, share experiences, and access a vast repository of medical knowledge. MedPeer aims to enhance the quality of medical care by facilitating the exchange of professional knowledge among healthcare providers.
How the Company Makes MoneyMedPeer, Inc. generates revenue through a combination of membership fees from participating healthcare professionals and advertising fees from pharmaceutical companies and other entities targeting medical professionals. The company also offers premium services and features to its users, which contribute to its revenue. Additionally, partnerships with healthcare institutions and research organizations may offer further revenue opportunities through collaborative projects and data-driven studies.

MedPeer, Inc. Financial Statement Overview

Summary
MedPeer, Inc. exhibits solid financial performance with strong revenue and profit growth, efficient cost management, and low leverage. The income statement and balance sheet reflect overall financial health. However, cash flow management needs attention to support long-term growth and operational resilience.
Income Statement
85
Very Positive
MedPeer, Inc. demonstrates strong revenue growth with a notable increase from 2022 to TTM 2024. The gross profit margin is robust, indicating efficient cost management. While the net profit margin is healthy, the slight decline in EBIT margin suggests increasing operational expenses. Overall, the income statement reflects a solid financial performance with room for margin improvement.
Balance Sheet
80
Positive
The balance sheet is strong with a low debt-to-equity ratio, indicating financial stability and low leverage risk. The equity ratio highlights a solid asset base supported by equity. Return on Equity (ROE) is commendable, showing efficient use of shareholder funds. However, the slight increase in total liabilities requires monitoring to ensure continued financial health.
Cash Flow
70
Positive
Cash flow analysis shows mixed results. The operating cash flow has significantly increased, demonstrating enhanced cash-generating capability. Free cash flow has grown, but the absence of recent data limits a complete trend analysis. The ratio of operating cash flow to net income is favorable, suggesting good cash conversion. Continued focus on sustaining cash flow growth is necessary.
Breakdown
TTMSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income StatementTotal Revenue
14.32B14.95B14.54B8.45B7.44B5.31B
Gross Profit
6.48B6.87B6.87B5.03B4.85B3.51B
EBIT
1.32B1.29B1.12B1.06B1.78B1.10B
EBITDA
1.72B3.01B1.87B1.30B1.98B1.27B
Net Income Common Stockholders
1.52B1.48B617.68M812.39M1.29B725.97M
Balance SheetCash, Cash Equivalents and Short-Term Investments
7.13B7.28B5.39B6.14B5.70B4.70B
Total Assets
15.36B15.55B15.16B9.35B8.54B7.13B
Total Debt
3.04B3.16B3.81B179.12M136.32M202.90M
Net Debt
-4.09B-4.12B-1.58B-5.96B-5.57B-4.50B
Total Liabilities
5.67B6.10B6.57B1.49B1.56B1.55B
Stockholders Equity
9.69B9.45B8.30B7.59B6.71B5.35B
Cash FlowFree Cash Flow
0.001.63B494.10M691.01M1.11B758.87M
Operating Cash Flow
0.001.89B600.07M853.23M1.36B930.30M
Investing Cash Flow
0.001.27B-5.01B-422.88M-345.39M-469.23M
Financing Cash Flow
0.00-1.27B3.67B7.08M-15.44M1.11B

MedPeer, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price720.00
Price Trends
50DMA
560.82
Positive
100DMA
520.09
Positive
200DMA
530.14
Positive
Market Momentum
MACD
47.93
Positive
RSI
66.02
Neutral
STOCH
31.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6095, the sentiment is Positive. The current price of 720 is below the 20-day moving average (MA) of 728.00, above the 50-day MA of 560.82, and above the 200-day MA of 530.14, indicating a bullish trend. The MACD of 47.93 indicates Positive momentum. The RSI at 66.02 is Neutral, neither overbought nor oversold. The STOCH value of 31.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6095.

MedPeer, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
¥19.08B17.42
2.10%12.51%9.68%
74
Outperform
¥16.11B9.30
0.61%-12.13%291.07%
67
Neutral
¥10.35B21.63
2.77%9.21%-20.04%
65
Neutral
¥19.77B20.19
1.57%17.20%20.25%
54
Neutral
$5.41B3.27-45.10%3.29%16.81%0.02%
45
Neutral
¥11.01B
-79.38%-1239.83%
43
Neutral
¥15.75B4,465.71
1.60%-7.98%-181.00%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:6095
MedPeer, Inc.
738.00
144.57
24.36%
JP:3649
FINDEX Inc.
753.00
-289.33
-27.76%
JP:3902
Medical Data Vision Co.Ltd.
394.00
-168.19
-29.92%
JP:3939
Kanamic Network Co., LTD.
405.00
-167.09
-29.21%
JP:4263
SUSMED,Inc.
664.00
67.00
11.22%
JP:4320
CE Holdings Co., Ltd.
651.00
88.98
15.83%

MedPeer, Inc. Corporate Events

MedPeer Announces Amendments to MBO Tender Offer Notice
May 15, 2025

MedPeer, Inc. announced amendments to its previously published notice regarding the implementation of a Management Buyout (MBO) and a recommendation to tender shares. The amendments clarify the intentions of Mr. Yo Iwami, a significant shareholder, to release collateralized shares and participate in the tender offer. The company plans to finance the tender offer through a bank loan from MUFG Bank and an equity investment, with the acquired shares and certain company assets pledged as collateral.

MedPeer, Inc. Announces Management Buyout and Delisting Plans
May 14, 2025

MedPeer, Inc. has announced a management buyout (MBO) involving a tender offer by NMT, Inc. to purchase its common shares, with the intention of taking the company private and delisting its shares. The board has expressed support for the tender offer, recommending shareholders to tender their shares, while leaving stock acquisition rights holders to decide independently. This move is expected to retract MedPeer’s plan for compliance with continued listing criteria, impacting its market presence and shareholder dynamics.

NMT, Inc. Launches Tender Offer for MedPeer, Inc. Shares
May 14, 2025

NMT, Inc. has announced a tender offer to acquire all shares of MedPeer, Inc., aiming to delist the company from the Tokyo Stock Exchange. This move, characterized as a management buyout, will see NMT’s founder, Yo Iwami, maintaining involvement in MedPeer’s operations, potentially impacting stakeholders by consolidating control and potentially reshaping the company’s strategic direction.

MedPeer, Inc. Reports Decline in Financial Results Amidst Market Challenges
May 14, 2025

MedPeer, Inc. reported a decline in its consolidated financial results for the six months ended March 31, 2025, with net sales and operating profits experiencing significant decreases compared to the previous year. Despite the downturn in sales, the company saw a substantial increase in profit attributable to owners of the parent, indicating improved efficiency or cost management. The forecast for the fiscal year ending September 30, 2025, suggests further declines in sales and profits, posing challenges for the company’s future growth and market positioning.

MedPeer, Inc. Supports Tender Offer and Plans Delisting
May 14, 2025

MedPeer, Inc. has announced its support for a tender offer by NMT, Inc. to purchase its common stock and stock acquisition rights, with plans to delist the company shares following the offer. This decision leads to the retraction of MedPeer’s previously announced compliance plan for continued listing criteria, indicating a strategic shift in the company’s market approach and potential implications for its shareholders.

MedPeer Revises Dividend Forecast Amid Tender Offer Plans
May 14, 2025

MedPeer, Inc. announced a revision to its dividend forecast for the fiscal year ending September 2025, deciding not to distribute year-end dividends. This decision aligns with the company’s support for a tender offer by NMT, Inc., which aims to take MedPeer private and delist its shares. The tender offer price assumes no year-end dividends, reflecting a strategic shift in the company’s financial planning and shareholder returns policy.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.